APA

NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

Medifocus Inc. ("Medifocus" or the "Company") (TSX VENTURE:MFS)(PINK
SHEETS:MDFZF) announces, subject to regulatory approval, an arm's length
non-brokered private placement of 1,000,000 units (the "Units") at a price of
$0.30 per Unit for gross proceeds of $300,000. Each Unit is comprised of one
Common Share and one-half Series A Common Share purchase warrant. Each whole
Series A Common Share purchase warrant will entitle the holder to purchase one
additional Medifocus Common Share at a price of $0.45 for a period of 18 months
following the completion of the offering.


The net proceeds of this offering will be primarily used by Medifocus to
initiate a pivotal phase III clinical trial using Medifocus Microfocus APA 1000
System for the treatment of breast cancer (including all related professional
expenses) and for working capital.


Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array ("APA") technology), which can precisely target and control
microwave energy to cause heating in cancerous tumors anywhere in the body
reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures, to
treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger the
targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the Massachusetts
Institute of Technology, Medifocus has further refined the precision of the
microwave focusing and control ability and developed a commercial system
dedicated exclusively for the treatment of Breast Cancer. Please visit
www.medifocusinc.com for more details.

AlliancePharma Inc. (TSXV:APA)
Historical Stock Chart
From Jun 2024 to Jul 2024

AlliancePharma Inc. (TSXV:APA)
Historical Stock Chart
From Jul 2023 to Jul 2024